Lutetium-177 | search
Click here to view Lutetium-177 news from 60+ newspapers.
Bookmark or Share- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate ...Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers...
- PLUVICTO™ | Lutetium Lu 177 vipivotide tetraxetanWhat is PLUVICTO ® (lutetium Lu 177 vipivotide tetraxetan)? PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...
- Lutetium-177 iPSMA for Prostate Cancer | Open MedscienceSummary: Lutetium-177 iPSMA, developed by ININ and the National Cancer Institute of Mexico City, represents a breakthrough in the treatment of metastasized prostate cancer.Acting as the therapeutic counterpart to the imaging agent 99m Tc-iPSMA, it utilises the prostate-specific membrane antigen (PSMA) pathway to deliver targeted beta radiation therapy.
- Lutetium (177Lu) oxodotreotide - WikipediaLutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] .
- Lutetium-177 shows significant rPFS benefit for ... - Mayo ClinicMayo Clinic researchers found that lutetium-177 (177 Lu)-PSMA-617 prolonged radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who were taxane-naive and had progressive disease after receiving androgen receptor pathway inhibition (ARPI) therapy compared with those ...
More
